{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Any laboratory result abnormality fulfilling the criteria for a serious adverse event (SAE) should', 'be reported as such, in addition to being recorded as an adverse event in the eCRF.', '6.2.2 Handling and Reporting of Safety Parameters', '6.2.2.1', 'Serious Adverse Events', 'For each patient any clinical adverse event or abnormal laboratory test value that is serious', 'occurring during the course of the study from the date of first study treatment until up to 4', 'weeks after the last dose of study treatment, must be reported immediately, without undue', 'delay, but not later than 24 hours after recognition or receiving knowledge to CRO via fax or', 'email with a completed SAE Report Form to the Sponsor and coordinating investigator. If', 'missing information about a SAE cannot be collected, the SAE should be reported', 'immediately, without undue delay, but not later than 24 hours and the missing information sent', 'later as a follow-up report as soon as possible.', 'The coordinating investigator as the sponsors authorized representative will medically review', 'all SAE reports (second assessment of the SAE) within 3 calendar days, for fatal and life-', 'threatening SAEs within one calendar day, with regard to:', 'Relationship to study treatment', 'Expectedness', 'Change of risk-benefit relation of the study', 'The Sponsor and the CRO will ensure compliance with all regulatory reporting requirements', 'including the notification of the appropriate Ethics Committees, Competent Authorities and', 'participating investigators of all serious adverse events occurring at the sites in accordance', 'with national laws of Germany, ICH Good Clinical Practice and European/EMA requirements.', 'Expectedness of any SAE will be assessed by means of the reference safety information in', 'the current version of the respective SmPC for standard chemotherapy medications. Every', 'SAE, being assessed by either the investigator or the sponsor (respectively the coordinating', 'investigator) as related to study drug und assessed as being either unexpected or unexpected', 'with regard to outcome or severity of the event will be reported as SUSAR to the competent', 'authorities, responsible ethics committee and investigators of the trial in line with the national', 'regulations in effect (German drug law [AMG] and GCP-V).', 'Fatal or life-threatening SUSARs must be reported within 7 days, all others need to be reported', 'within 15 days. Also, all events which can change the risk-benefit ratio of the study drug have', 'to be reported within 15 days in the same way as SUSARs.', 'Once a year throughout the clinical trial or on demand, the sponsor will provide the competent', 'authorities and the responsible ethics committee with the annual safety report in the format of', 'the Development Safety Update Report (DSUR) in accordance with European and national', 'regulations (GCP-V).', 'Misuse, abuse and overdose of study medication (i.e. higher dose than stipulated by the', 'protocol) have to be reported to the Sponsor and the CRO within 15 days of identification.', 'Confidential', 'Page 56 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Cases of misuse, abuse or overdose that lead to serious adverse reactions should be reported', 'on an expedited basis with a completed and faxed or emailed SAE Report Form.', '6.2.2.2 Treatment and Follow-up of Adverse Events', 'Adverse events, especially those for which the relationship to the study medication is related,', 'should be followed up until they have returned to baseline status or stabilized. If a clear', 'explanation is established, it should be recorded on the eCRF.', '6.2.2.3 Follow-up of Abnormal Laboratory Test Values', 'In the event of unexplained abnormal laboratory test values, the tests should be repeated', 'immediately and followed up until they have returned to the normal range and/or an adequate', 'explanation of the abnormality is found. If a clear explanation is established, it should be', 'recorded on the eCRF.', '6.2.2.4 Adverse drug reactions with Concomitant Medication', 'The investigators must be aware that for all concomitant medications the regulations of post', 'marketing reporting for suspected adverse drug reactions apply, i.e. reporting to the marketing', 'authorization holder or the local regulatory bodies.', '6.2.2.5 Pregnancy and Exposure During Breastfeeding', 'Although pregnancy and infant exposure during breastfeeding are not considered AEs, any', 'pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to', 'the investigator or their designee) that occurs during the study are reportable to the sponsor', 'or designee.', 'All reported pregnancies must be followed to the completion/termination of the pregnancy.', 'Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole,', 'blighted ovum, fetal death, intrauterine death, miscarriage and stillbirth must be reported as', 'serious adverse events. If the pregnancy continues to term, the outcome (health of infant) must', 'also be reported.', 'SAE reports and any other relevant safety information are to be forwarded to the', 'Institut f\u00fcr Klinische Krebsforschung IKF GmbH:', 'IKF Safety facsimile number: +49 / (0)69 / 7601 - - 3655', 'or', 'email: sae@ikf-khnw.de', 'Confidential', 'Page 57 of 79']\n\n###\n\n", "completion": "END"}